What is Tirzepatide?
Tirzepatide is a dual GIP (Glucose-dependent Insulinotropic Polypeptide) and GLP-1 (Glucagon-Like Peptide-1) receptor agonist developed by Eli Lilly. FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for weight management, it represents the first approved dual incretin receptor agonist. Clinical trials (SURMOUNT-1) demonstrated up to 22.5% body weight reduction, establishing it as one of the most clinically effective weight management compounds studied to date.
Research Benefits
- Dual GIP/GLP-1 agonism produces superior weight loss versus GLP-1-only agonists
- SURMOUNT-1 trial showed up to 22.5% body weight reduction at maximum dose
- Significantly improves HbA1c, fasting glucose, and insulin sensitivity
- Reduces cardiovascular risk markers including blood pressure and LDL cholesterol
- GIP component enhances tolerability versus pure GLP-1 agonists at equivalent doses
- Weekly dosing via subcutaneous injection with once-daily extended pharmacokinetics
Dosage & Protocol
Research follows the clinical titration protocol: 2.5 mg/week for 4 weeks, increasing by 2.5 mg every 4 weeks to a maximum of 15 mg/week. The ~5-day half-life enables stable once-weekly dosing. Dose escalation is essential to minimize gastrointestinal adverse effects.
Frequently Asked Questions
Tirzepatide's dual GIP/GLP-1 mechanism produced 22.5% weight loss vs semaglutide's ~15% in head-to-head analyses. The GIP component also improves tolerability and may enhance the anabolic preservation of lean mass, making tirzepatide the current gold standard in GLP-1-class research.
Standard protocol starts at 2.5 mg/week for 4 weeks, then increases by 2.5 mg every 4 weeks: 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg. Slow titration minimizes nausea and GI discomfort.
Clinical trials ran 72 weeks for full dose exploration. Most research protocols run 16–24 weeks, with significant body composition changes measurable from 8 weeks onwards. The 5-day half-life means effects persist for nearly a week after each injection.